The research was from Duke University from Duke University, East Carolina University, Yale University and Humacyte , and was funded by Humacyte, a leader in regenerative medicine. Supervision of Research and senior author of the article was Laura Niklason, founder of Humacyte and Professor of Anesthesiology and of Biomedical Engineering at Yale University. Niklason is a recognized authority in regenerative medicine for arterial engineering and was the head of the team. Recently a functioning rat lung in a laboratory – Not only leads at the time of the patient are necessary engineered, but the ability to generate a significant number of grafts from a cell bank is allow reducing the final production costs, as in other regenerative medicine strategies compared, added lead author Shannon LM ,, Senior Director of Scientific Operations and Co-Founder of Humacyte, While there is still considerable research to be done before a product is for widespread use, we are strongly of the findings outlined in this paper encourages and eager to move forward with additional additional study, Dahl..
Currently, grafting using the patient’s own veins remains the gold standard. Harvesting a vein from the patient’s leg can lead to complications, and for patients who are not suitable veins, the bioengineered veins could be an important new way to serve bypass a coronary. .. Coronary Artery Bypass Graft The American Heart Association Update on Heart Disease Statistics reports that in 2007 in the U.S., just over 400,000 coronary bypass operations were performed. Read more »